Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

NCT02109341 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT02109341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02109341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2014
Completion date
January 31, 2016
Enrollment
148 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer